Breast (Edinburgh, Scotland)Review
14 Nov 2024
Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD).
Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT).
This has become a valid ablative treatment option for OMD patients. However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients.
We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Given her role as Editorial Board Member, Serena Di Cosimo had no involvement in the peer-review of this article and has no involvement in the peer review of this article and has no access to information regarding its peer review.
More resources:
Share: